In the News

aam policy agenda 117th congress
February 22, 2021
The Association for Accessible Medicines (AAM) and its Biosimilars Council shared their policy priorities for the Biden administration and 117th Congress, highlighting solutions to maintain the sustainability of generic and biosimilar competition.
part d statement
January 15, 2021
AAM and its Biosimilars Council applaud the decision by CMS to update the Part D program and allow plans with lower cost-sharing.
biosimilars news april 2020
December 10, 2020
AAM and its Biosimilars Council look forward to working with President-elect Biden’s U.S. Trade Representative (USTR)-designee Katherine Tai.
Xavier Becerra
December 7, 2020
AAM and its members look forward to working with Xavier Becerra to secure patient access to safe, effective and affordable medicines.
igba global biosimilars week
November 15, 2020
IGBA launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative.
Approved Biosimilars
November 11, 2020
The Association for Accessible Medicines looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to safe, effective and affordable generic and biosimilar prescription medicines for all Americans.

Recent Tweets

[email protected] strongly supports President Biden's America's Supply Chains Executive Order as an important step toward strengthening the U.S. pharmaceutical supply chain and improving patient access to lower-cost #generics and #biosimilars.

Statement: https://accessiblemeds.org/resources/press-releases/aam-statement-president-bidens-supply-chain-executive-order

Load More...